An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs ASP 5878 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 06 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.